Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview

Rodolfo Montironi, Matteo Santoni, Antonio Lopez-Beltran, Liang Cheng, Holger Moch, Marina Scarpelli

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This contribution gives an overview of recent insights and emerging strategies for individualized therapeutic approaches based on genomic and cancer molecular profiles in patients with a morphological diagnosis of renal, bladder and prostate tumors. Significant advances have been made in molecular biology technologies, such as next-generation sequencing and whole-exome sequencing. The rise of such novel techniques has increased our knowledge on tumor cell biology and cancer development, thus allowing us to identify complex genomic abnormalities. These findings have paved the way to provide healthcare from an individual perspective. An emerging strategy to individualize therapeutic interventions is focused on stem cells. Because of their unique characteristics, they are among the most promising candidates as potential vectors carrying suicide genes into different types of cancer, including genitourinary tumors. Another emerging strategy could be based on prostate specific membrane antigen (PSMA), a unique membrane-bound glycoprotein, which is overexpressed manifold in prostate cancer. PSMA can serve as target for delivering therapeutic agents such as cytotoxins or radionuclides.

Original languageEnglish (US)
Pages (from-to)96-102
Number of pages7
JournalCurrent Drug Targets
Volume16
Issue number2
StatePublished - 2015

Fingerprint

Urogenital Neoplasms
Tumors
Cytology
Neoplasms
Molecular biology
Cytotoxins
Exome
Stem cells
Radioisotopes
Membrane Glycoproteins
Glycoproteins
Genes
Urinary Bladder Neoplasms
Suicide
Membranes
Cell Biology
Prostate
Molecular Biology
Prostatic Neoplasms
Stem Cells

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Montironi, R., Santoni, M., Lopez-Beltran, A., Cheng, L., Moch, H., & Scarpelli, M. (2015). Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview. Current Drug Targets, 16(2), 96-102.

Morphologic and molecular backgrounds for personalized management of genito-urinary cancers : an overview. / Montironi, Rodolfo; Santoni, Matteo; Lopez-Beltran, Antonio; Cheng, Liang; Moch, Holger; Scarpelli, Marina.

In: Current Drug Targets, Vol. 16, No. 2, 2015, p. 96-102.

Research output: Contribution to journalArticle

Montironi, R, Santoni, M, Lopez-Beltran, A, Cheng, L, Moch, H & Scarpelli, M 2015, 'Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview', Current Drug Targets, vol. 16, no. 2, pp. 96-102.
Montironi, Rodolfo ; Santoni, Matteo ; Lopez-Beltran, Antonio ; Cheng, Liang ; Moch, Holger ; Scarpelli, Marina. / Morphologic and molecular backgrounds for personalized management of genito-urinary cancers : an overview. In: Current Drug Targets. 2015 ; Vol. 16, No. 2. pp. 96-102.
@article{2634fe7913cc4e038bbdd4bd109f25ab,
title = "Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview",
abstract = "This contribution gives an overview of recent insights and emerging strategies for individualized therapeutic approaches based on genomic and cancer molecular profiles in patients with a morphological diagnosis of renal, bladder and prostate tumors. Significant advances have been made in molecular biology technologies, such as next-generation sequencing and whole-exome sequencing. The rise of such novel techniques has increased our knowledge on tumor cell biology and cancer development, thus allowing us to identify complex genomic abnormalities. These findings have paved the way to provide healthcare from an individual perspective. An emerging strategy to individualize therapeutic interventions is focused on stem cells. Because of their unique characteristics, they are among the most promising candidates as potential vectors carrying suicide genes into different types of cancer, including genitourinary tumors. Another emerging strategy could be based on prostate specific membrane antigen (PSMA), a unique membrane-bound glycoprotein, which is overexpressed manifold in prostate cancer. PSMA can serve as target for delivering therapeutic agents such as cytotoxins or radionuclides.",
author = "Rodolfo Montironi and Matteo Santoni and Antonio Lopez-Beltran and Liang Cheng and Holger Moch and Marina Scarpelli",
year = "2015",
language = "English (US)",
volume = "16",
pages = "96--102",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Morphologic and molecular backgrounds for personalized management of genito-urinary cancers

T2 - an overview

AU - Montironi, Rodolfo

AU - Santoni, Matteo

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Moch, Holger

AU - Scarpelli, Marina

PY - 2015

Y1 - 2015

N2 - This contribution gives an overview of recent insights and emerging strategies for individualized therapeutic approaches based on genomic and cancer molecular profiles in patients with a morphological diagnosis of renal, bladder and prostate tumors. Significant advances have been made in molecular biology technologies, such as next-generation sequencing and whole-exome sequencing. The rise of such novel techniques has increased our knowledge on tumor cell biology and cancer development, thus allowing us to identify complex genomic abnormalities. These findings have paved the way to provide healthcare from an individual perspective. An emerging strategy to individualize therapeutic interventions is focused on stem cells. Because of their unique characteristics, they are among the most promising candidates as potential vectors carrying suicide genes into different types of cancer, including genitourinary tumors. Another emerging strategy could be based on prostate specific membrane antigen (PSMA), a unique membrane-bound glycoprotein, which is overexpressed manifold in prostate cancer. PSMA can serve as target for delivering therapeutic agents such as cytotoxins or radionuclides.

AB - This contribution gives an overview of recent insights and emerging strategies for individualized therapeutic approaches based on genomic and cancer molecular profiles in patients with a morphological diagnosis of renal, bladder and prostate tumors. Significant advances have been made in molecular biology technologies, such as next-generation sequencing and whole-exome sequencing. The rise of such novel techniques has increased our knowledge on tumor cell biology and cancer development, thus allowing us to identify complex genomic abnormalities. These findings have paved the way to provide healthcare from an individual perspective. An emerging strategy to individualize therapeutic interventions is focused on stem cells. Because of their unique characteristics, they are among the most promising candidates as potential vectors carrying suicide genes into different types of cancer, including genitourinary tumors. Another emerging strategy could be based on prostate specific membrane antigen (PSMA), a unique membrane-bound glycoprotein, which is overexpressed manifold in prostate cancer. PSMA can serve as target for delivering therapeutic agents such as cytotoxins or radionuclides.

UR - http://www.scopus.com/inward/record.url?scp=84924312439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924312439&partnerID=8YFLogxK

M3 - Article

C2 - 25469883

AN - SCOPUS:84924312439

VL - 16

SP - 96

EP - 102

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -